• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas.

作者信息

La Rosa Alonso, Gutierrez Alonso N, Odia Yazmin, McDermott Michael W, Ahluwalia Manmeet S, Mehta Minesh P, Kotecha Rupesh

机构信息

Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.

Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.

出版信息

Neurooncol Adv. 2023 Jun 15;5(1):vdad074. doi: 10.1093/noajnl/vdad074. eCollection 2023 Jan-Dec.

DOI:10.1093/noajnl/vdad074
PMID:37358937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10290511/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/550c/10290511/f42ec544c5a8/vdad074_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/550c/10290511/f42ec544c5a8/vdad074_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/550c/10290511/f42ec544c5a8/vdad074_fig1.jpg

相似文献

1
Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas.复发性高级别胶质瘤的时间调制脉冲质子再照射（TMPPR）
Neurooncol Adv. 2023 Jun 15;5(1):vdad074. doi: 10.1093/noajnl/vdad074. eCollection 2023 Jan-Dec.
2
Proton re-irradiation of unresectable recurrent brain gliomas: clinical outcomes and toxicity.无法切除的复发性脑胶质瘤的质子再放疗：临床结果和毒性。
J BUON. 2021 May-Jun;26(3):970-976.
3
Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas.在选定的复发性高级别胶质瘤患者中，使用调强放疗联合替莫唑胺进行再放疗后的生存情况。
Ann Transl Med. 2015 Nov;3(20):304. doi: 10.3978/j.issn.2305-5839.2015.11.29.
4
A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.复发性高级别胶质瘤患者再放疗的回顾性研究。
Clin Oncol (R Coll Radiol). 2018 Sep;30(9):563-570. doi: 10.1016/j.clon.2018.05.004. Epub 2018 Jun 8.
5
Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.贝伐珠单抗联合或不联合再放疗治疗复发性或进展性高级别胶质瘤的挽救治疗。
J Neurooncol. 2013 Mar;112(1):133-9. doi: 10.1007/s11060-013-1044-3. Epub 2013 Jan 12.
6
Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas.复发性高级别胶质瘤的同期高热与再放疗。
Neoplasma. 2017;64(5):803-808. doi: 10.4149/neo_2017_520.
7
Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma.复发性高级别胶质瘤患者剂量递增再照射的临床结果
Neurooncol Pract. 2022 May 2;9(5):390-401. doi: 10.1093/nop/npac032. eCollection 2022 Oct.
8
Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction.评估利用质子铅笔束扫描技术治疗原发性或复发性食管和胃食管交界处恶性肿瘤的患者的结局。
J Thorac Oncol. 2020 Jun;15(6):1054-1064. doi: 10.1016/j.jtho.2020.01.024. Epub 2020 Mar 4.
9
Re-irradiation with Moderate Hypo-fractionation Using Intensity Modulated Photon or Proton Radiation Therapy in Locally Recurrent Squamous Cell Carcinoma of Nasopharynx.局部复发性鼻咽癌采用调强光子或质子放射治疗适度低分割再放疗。
Cancer Res Treat. 2022 Jan;54(1):96-108. doi: 10.4143/crt.2020.1349. Epub 2021 Mar 26.
10
Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.复发性高级别胶质瘤再放疗时机：单机构研究。
J Neurooncol. 2018 Jul;138(3):571-579. doi: 10.1007/s11060-018-2824-6. Epub 2018 Mar 8.

引用本文的文献

1
Initial feasibility cohort of temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade intracranial malignancies.暂时调制脉冲质子再放疗（TMPPR）治疗复发性高级别颅内恶性肿瘤的初步可行性队列研究。
Sci Rep. 2024 Nov 4;14(1):26685. doi: 10.1038/s41598-024-78370-x.
2
Radiotherapeutic advances in the management of glioblastoma.胶质母细胞瘤治疗中的放射治疗进展
J Neurooncol. 2024 Dec;170(3):509-520. doi: 10.1007/s11060-024-04824-x. Epub 2024 Sep 13.

本文引用的文献

1
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.基于客观缓解率与中位总生存期之间的历史关联，为复发性胶质母细胞瘤临床试验设定客观缓解率目标。
Neuro Oncol. 2023 Jun 2;25(6):1017-1028. doi: 10.1093/neuonc/noad002.
2
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.NRG Oncology/RTOG1205：贝伐珠单抗联合再放疗与贝伐珠单抗单药治疗复发性胶质母细胞瘤的随机 II 期试验。
J Clin Oncol. 2023 Feb 20;41(6):1285-1295. doi: 10.1200/JCO.22.00164. Epub 2022 Oct 19.
3
Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results.
复发性原发性中枢神经系统恶性肿瘤的脉冲式低剂量率（PRDR）放疗：剂量学和临床结果
Cancers (Basel). 2022 Jun 15;14(12):2946. doi: 10.3390/cancers14122946.
4
Pulsed low dose-rate radiotherapy: radiobiology and dosimetry.脉冲低剂量率放射治疗：放射生物学和剂量学。
Phys Med Biol. 2022 Jan 28;67(3). doi: 10.1088/1361-6560/ac4c2f.
5
Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.脉冲低剂量率放疗联合或不联合贝伐珠单抗治疗复发性高级别胶质瘤：生存结果。
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):979-986. doi: 10.1016/j.ijrobp.2020.06.020. Epub 2020 Jun 27.
6
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.IDH1 突变抑制剂 AGI-5198 对 IDH1 突变型癌细胞的放射防护作用。
Cancer Res. 2015 Nov 15;75(22):4790-802. doi: 10.1158/0008-5472.CAN-14-3603. Epub 2015 Sep 11.
7
Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy.大体积复发性脑胶质瘤的脉冲低剂量率放疗再照射。
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):835-41. doi: 10.1016/j.ijrobp.2009.11.058. Epub 2010 May 14.
8
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.高级别胶质瘤更新后的反应评估标准：神经肿瘤学工作组的反应评估。
J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
9
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.复发性胶质母细胞瘤中，先使用单药贝伐单抗，肿瘤进展时再使用贝伐单抗联合伊立替康的II期试验。
J Clin Oncol. 2009 Feb 10;27(5):740-5. doi: 10.1200/JCO.2008.16.3055. Epub 2008 Dec 29.